Skip to main content

Cabozantinib: A MET, RET, and VEGFR2 Tyrosine Kinase Inhibitor

Part of the Recent Results in Cancer Research book series (RECENTCANCER,volume 201)

Abstract

Cabozantinib is a receptor tyrosine kinase inhibitor with activity against MET, VEGFR2, FLT3, c-KIT, and RET. Activity of cabozantinib toward a broad range of tumor models could be detected in several preclinical studies. Of note, cabozantinib decreases metastasis potential and tumor invasiveness when compared with placebo or agents that target VEGFR and have no activity against MET. Clinical phase I and II studies with cabozantinib have been conducted in various malignancies including medullary thyroid cancer (MTC), NSCLC, breast, ovarian, pancreatic, and prostate cancer. In MTC, gain of function mutations of RET are central for tumorigenesis. Hereditary forms of MTC (MEN II) are caused by germline mutations of RET, in sporadic MTC in up to 50 % of cases RET mutations occur. Additionally, activating molecular changes in VEGFR and MET pathways have also been implicated in MTC progression. Clinical responses with cabozantinib in MTC could be observed in early clinical trials, and following confirmation of clinical benefit in a randomized phase III trial, cabozantinib gained FDA approval for first-line treatment of advanced MTC in 2012. In prostate cancer models, MET expression increases with androgen ablation and clinical progression of bone and lymph node metastasis. A phase II trial with cabozantinib also showed very promising response rates in patients with metastatic prostate cancer. Therefore, randomized phase III studies are currently ongoing to validate the efficacy of cabozantinib in heavily pretreated prostate cancer patients.

Keywords

  • Prostate Cancer
  • Hepatocyte Growth Factor
  • Tyrosine Kinase Inhibitor
  • Maximum Tolerate Dose
  • Medullary Thyroid Cancer

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-642-54490-3_12
  • Chapter length: 8 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   109.00
Price excludes VAT (USA)
  • ISBN: 978-3-642-54490-3
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   149.00
Price excludes VAT (USA)
Hardcover Book
USD   169.99
Price excludes VAT (USA)

References

  • Bean J et al (2007) MET amplification occurs with or without T790 M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104(52):20932–20937

    CAS  PubMed Central  PubMed  CrossRef  Google Scholar 

  • Bussolino F et al (1992) Hepatocyte growth-factor is a potent angiogenic factor which stimulates endothelial-cell motility and growth. J Cell Biol 119(3):629–641

    CAS  PubMed  CrossRef  Google Scholar 

  • Direnzo MF et al (1995) Overexpression and amplification of the Met/Hgf receptor gene during the progression of colorectal-cancer. Clin Cancer Res 1(2):147–154

    CAS  Google Scholar 

  • Houldsworth J et al (1990) Gene amplification in gastric and esophageal adenocarcinomas. Cancer Res 50(19):6417–6422

    CAS  PubMed  Google Scholar 

  • Kurzrock R et al (2011) Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 29(19):2660–2666

    CAS  PubMed Central  PubMed  CrossRef  Google Scholar 

  • Matsumoto K, Nakamura T (2001) Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. Kidney Int 59(6):2023–2038

    CAS  PubMed  CrossRef  Google Scholar 

  • Michalopoulos GK, DeFrances MC (1997) Liver regeneration. Science 276(5309):60–66

    CAS  PubMed  CrossRef  Google Scholar 

  • Mizuno S, Matsumoto K, Nakamura T (2001) Hepatocyte growth factor suppresses interstitial fibrosis in a mouse model of obstructive nephropathy. Kidney Int 59(4):1304–1314

    CAS  PubMed  CrossRef  Google Scholar 

  • Nakagawa T et al (2012) Combined therapy with mutant-selective EGFR inhibitor and met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol Cancer Ther 11(10):2149–2157

    CAS  PubMed  CrossRef  Google Scholar 

  • Schmidt L et al (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16(1):68–73

    CAS  PubMed  CrossRef  Google Scholar 

  • Schoffski P et al (2012) An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. J Clin Oncol 30(15)

    Google Scholar 

  • Sennino B et al (2012) Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2(3):270–287

    CAS  PubMed Central  PubMed  CrossRef  Google Scholar 

  • Sirotnak FM et al (2004) Microarray analysis of progression to reduced prostate cancer androgen dependence: studies in unique models contrasts early and late molecular events. Mol Carcinog 41(3):150–163

    CAS  PubMed  CrossRef  Google Scholar 

  • Smith DC et al (2013) Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 31(4):412–419

    CAS  PubMed  CrossRef  Google Scholar 

  • Soman NR et al (1991) The Tpr-Met oncogenic rearrangement is present and expressed in human gastric-carcinoma and precursor lesions. Proc Natl Acad Sci USA 88(11):4892–4896

    CAS  PubMed Central  PubMed  CrossRef  Google Scholar 

  • Takayama H et al (1996) Scatter factor/hepatocyte growth factor as a regulator of skeletal muscle and neural crest development. Proc Natl Acad Sci USA 93(12):5866–5871

    CAS  PubMed Central  PubMed  CrossRef  Google Scholar 

  • Trusolino L, Comoglio PM (2002) Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2(4):289–300

    CAS  PubMed  CrossRef  Google Scholar 

  • Verras M et al (2007) The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res 67(3):967–975

    CAS  PubMed  CrossRef  Google Scholar 

  • Yakes FM et al (2011) Cabozantinib (XL184), a Novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 10(12):2298–2308

    CAS  PubMed  CrossRef  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Carsten Grüllich .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Grüllich, C. (2014). Cabozantinib: A MET, RET, and VEGFR2 Tyrosine Kinase Inhibitor. In: Martens, U. (eds) Small Molecules in Oncology. Recent Results in Cancer Research, vol 201. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-54490-3_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-54490-3_12

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-54489-7

  • Online ISBN: 978-3-642-54490-3

  • eBook Packages: MedicineMedicine (R0)